Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2013 Jul;98(7):995-7.
doi: 10.3324/haematol.2013.085779.

Circulating microparticles in children with sickle cell anemia: a heterogeneous procoagulant storm directed by hemolysis and fetal hemoglobin

Anna Falanga, Alice Trinchero
Editorial

Circulating microparticles in children with sickle cell anemia: a heterogeneous procoagulant storm directed by hemolysis and fetal hemoglobin

Anna Falanga et al. Haematologica. 2013 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Mixed microparticles in SCA children act at the interface between hemolysis and clotting activation. Microparticles (MPs) of different cellular origin (e.g. red blood cells, platelets, monocytes, granulocytes) are released upon hemolysis, blood cell apoptosis, and activation. Hemolysis increases when the physiological switch from fetal (HbF) to adult hemoglobin occurs and sickle cells (characterized by HbS) are produced. Vice versa, hemolysis decreases when hydroxyurea therapy is started, with subsequent upregulation of HbF (α2γ2) levels. On their surface MPs expose procoagulant phospholipids (i.e. phosphatidylserine, PS) and proteins (i.e. Tissue Factor, TF), and activate other blood cells (e.g. platelets, monocytes) and hemostasis. HbF levels inversely correlate to circulating MPs and regulate specific MP patterns, particularly those platelet-derived.
See this image and copyright information in PMC

References

    1. Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol. 2007;139(1):3–13 - PubMed
    1. Ataga KI, Brittain JE, Desai P, May R, Jones S, Delaney J, et al. Association of coagulation activation with clinical complications in sickle cell disease. PloS one. 2012;7(1):e29786. - PMC - PubMed
    1. Cappellini MD. Coagulation in the pathophysiology of hemolytic anemias. Hematology Am Soc Hematol Educ Program. 2007;74–8 - PubMed
    1. Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood. 2007;110(6):2166–72 - PMC - PubMed
    1. Setty BN, Kulkarni S, Rao a K, Stuart MJ. Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood. 2000;96(3):1119–24 - PubMed

Publication types

MeSH terms